Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01572805
Other study ID # ACTRN12612000117819
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received April 3, 2012
Last updated October 10, 2012
Start date February 2012
Est. completion date October 2012

Study information

Verified date October 2012
Source Qazvin University Of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of melatonin on pain and amount of blood loss after cesarean delivery one hundred twenty women with singleton term pregnancy undergoing elective or emergency lower segment cesarean section under spinal anesthesia were included in this study. The patients were randomly allocated to one of three groups of 40 each to receive sublingual 3 mg melatonin or 6 mg melatonin or placebo before spinal of anesthesia . In all patients 20 IU syntocinon which dissolved in 0.5liter of lactated Ringer's solution) at the rate of 500 ml over a 15 minutes period, immediately after delivery of the neonate was infused . Time to first requirement of analgesic supplement, Hemodynamic variables,will be recorded.Patients were instructed preoperatively in the use of the verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain) for pain assessment. If the VRS exceeded four and the patient requested a supplement analgesic, diclofenac Na supp 100 mg was to be given for post-operative pain relief as needed . For breakthrough pain(VRS >4) if time of administration of diclofenac Na less than 8h,Pethidine 25 mg IV was given. For determination of blood loss ,change in hemoglobin levels, need for additional oxytocics and ,the volume of blood in the suction bottle was measured, blood soaked sponges. Hemoglobin values were determined both before surgery and 12 h following surgery


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date October 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria:

- pregnant women at term (37—40 wks) gestation scheduled for either elective or emergency lower segment cesarean section

Exclusion Criteria:

- women with any risk factor associated with an increased risk of postpartum hemorrhage were excluded i.e. multiple gestation, antepartum hemorrhage,poly-hydramnios, two or more previous cesarean sections and/or a history of previous rupture uterus

- current or previous history of significant disease including heart disease, liver, renal disorders ,anemia (Hb8 g%)or known coagulopathy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
melatonin 3mg
To receive sublingual 3 mg melatonin before spinal of anesthesia .
melatonin 6mg
To receive sublingual 6 mg melatonin before spinal of anesthesia .
placebo
To receive sublingual placebo tablet before spinal of anesthesia .

Locations

Country Name City State
Iran, Islamic Republic of Qazvin Medical Science University Qazvin

Sponsors (1)

Lead Sponsor Collaborator
Qazvin University Of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first requirement of analgesic supplement Time to first requirement of analgesic supplement within 24 hours after intratechal injection Yes
Primary amount of blood loss after cesarean delivery during surgery Yes
Secondary hemodynamic variables 5min before the intrathecal injection,and at 2, 4, 6, 10, 15,20 min after the injection Yes